NeuropaceNPCE
Market Cap: $210M
About: NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all its revenue from the sales of RNS System to hospitals facilities (typically Level 4 CECs) that implant RNS System.
Employees: 179
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
10,600% more call options, than puts
Call options by funds: $214K | Put options by funds: $2K
31% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 13
3.61% less ownership
Funds ownership: 55.91% [Q1] → 52.3% (-3.61%) [Q2]
6% less funds holding
Funds holding: 54 [Q1] → 51 (-3) [Q2]
14% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 21
46% less capital invested
Capital invested by funds: $209M [Q1] → $114M (-$95.4M) [Q2]
50% less funds holding in top 10
Funds holding in top 10: 2 [Q1] → 1 (-1) [Q2]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
Cantor Fitzgerald Ross Osborn 32% 1-year accuracy 19 / 60 met price target | 150%upside $18 | Overweight Reiterated | 14 Aug 2024 |
Wells Fargo Vik Chopra 20% 1-year accuracy 1 / 5 met price target | 108%upside $15 | Overweight Maintained | 14 Aug 2024 |
Morgan Stanley Drew Ranieri 46% 1-year accuracy 6 / 13 met price target | 11%upside $8 | Equal-Weight Maintained | 15 Jul 2024 |
Financial journalist opinion
Based on 6 articles about NPCE published over the past 30 days